Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma
-
Wick, Antje (Heidelberg University Medical Center)
;
Desjardins, Annick (Duke University. The Preston Robert Tisch Brain Tumor Center at Duke) ;
Suárez, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Forsyth, Peter (H. Lee Moffitt Cancer Center and Research Institute) ;
Gueorguieva, Ivelina (Eli Lilly and Company) ;
Burkholder, Tiana (Eli Lilly and Company) ;
Cleverly, Ann Louise (Eli Lilly and Company) ;
Estrem, Shawn T. (Eli Lilly and Company) ;
Wang, Shuaicheng (BioStat Solutions (Estats Units)) ;
Lahn, Michael M.. (Eli Lilly and Company) ;
Guba, Susan C. (Eli Lilly and Company) ;
Capper, David (Charité - Universitätsmedizin Berlin) ;
Rodon Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Subscribe to this discussion. You will then receive all new comments by email.
guest ::
